Horizon Discovery Group plc Notice of Full Year Results (3682T)
20 March 2019 - 6:02PM
UK Regulatory
TIDMHZD
RNS Number : 3682T
Horizon Discovery Group plc
20 March 2019
Horizon Discovery Group plc
Notice of Full Year Results
Cambridge, UK, 20 March 2019: Horizon Discovery Group plc (LSE:
HZD) ("Horizon"), a global leader in the application of gene
editing and gene modulation technologies, today announces that its
full year results for the year ended 31 December 2018 will be
announced on Monday 29 April 2019.
Terry Pizzie, Chief Executive Officer, and Jayesh Pankhania,
Chief Financial Officer, will host a presentation for analysts and
live conference call at 12.00pm BST / 7:00am EST on the morning of
results at the offices of Numis, 10 Paternoster Square, London,
EC4M 7LT.
A live webcast of the meeting, with the presentation slides,
will be available on Horizon's Investor Relations website.
ENDS
For further information from Horizon Discovery Group plc, please
contact:
Horizon Discovery Group plc
Terry Pizzie, Chief Executive Officer
Jayesh Pankhania, Chief Financial Officer
Tel: +44 (0) 1223 655 580
Numis Securities Limited (Broker and NOMAD)
Freddie Barnfield / James Black / Duncan Monteith
Tel: +44 (0) 207 260 1000
Consilium Strategic Communications (Financial Media and Investor
Relations)
Mary-Jane Elliott / Matthew Neal / Melissa Gardiner
Tel: +44 (0) 20 3709 5701
Email: horizon@consilium-comms.com
About Horizon Discovery Group plc www.horizondiscovery.com
Horizon Discovery Group plc (LSE: HZD) ("Horizon") is a world
leader in gene editing and gene modulation technologies. Horizon
designs and engineers cells using its translational genomics
platform, a highly precise and flexible suite of DNA editing tools
(rAAV, ZFN, CRISPR, Transposon and base editing) and, following the
acquisition of Dharmacon, Inc., its functional genomics platform
comprising gene knockdown (RNAi) and gene expression (cDNA, ORF)
tools, for research and clinical applications that advance human
health. Horizon's platforms and capabilities enable researchers to
alter almost any gene or modulate its function in human or
mammalian cell-lines.
Horizon offers an extensive range of catalogue products and
related research services to support a greater understanding of the
function of genes across all species and the genetic drivers of
human disease and the development of personalised molecular, cell
and gene therapies. These have been adopted by over 10,000
academic, drug discovery, drug manufacturing and clinical
diagnostics customers around the globe, as well as in the Company's
own R&D pipeline.
Horizon is headquartered in Cambridge, UK, and is listed on the
London Stock Exchange's AIM market under the ticker HZD
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
END
NORDGGDXLBBBGCC
(END) Dow Jones Newswires
March 20, 2019 03:02 ET (07:02 GMT)
Horizon Discovery (LSE:HZD)
Historical Stock Chart
From Apr 2024 to May 2024
Horizon Discovery (LSE:HZD)
Historical Stock Chart
From May 2023 to May 2024